Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target-Reference-Cited by-同舟云学术

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

Published:2013-05-14 Issue:10 Volume:27 Page:1996-2005
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Harb J G,Neviani P,Chyla B J,Ellis J J,Ferenchak G J,Oaks J J,Walker C J,Hokland P,Roy D C,Caligiuri M A,Marcucci G,Huettner C S,Perrotti D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013151.pdf

Reference60 articles.

1. Cortes J, Kantarjian H . How I treat newly diagnosed chronic phase CML. Blood 2012; 120: 1390–1397.

2. Hehlmann R . How I treat CML blast crisis. Blood 2012; 120: 737–747.

3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (vol 23, pg 1054, 2009). Leukemia 2010; 24: 1102–1102.

4. Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254–2264.

5. Quintas-Cardama A, Cortes J . Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619–1630.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway;Toxicology and Applied Pharmacology;2023-09

2. Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia;Cancers;2023-02-03

3. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia;Biochemical Journal;2023-01-31

4. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia;Cell Death Discovery;2022-11-15

5. Therapeutic Strategies Against Cancer Stem Cells in Esophageal Carcinomas;Frontiers in Oncology;2021-02-16